What if fundraising stopped?

In a recent survey by the American Society of Clinical Oncology, about 35% of survey respondents reported that they had to terminate skilled research staff as a result of funding reductions. The result negatively impacts every level of research and is especially devastating since experts believe we are on the verge of making great strides in cancer treatment.

Great progress has been made in drug development, including Kadcyla® and many other cancer-specific drugs. Without a pipeline of investigators to continue this life-saving work, such progress will come to a halt.

Komen has invested more than $1 billion in breast cancer research, with more than $720 million of that since the start of the Susan G. Komen 3-Day®.

Current Komen funding allows for more than 200 active research grants in 30 states and 11 countries and totals over $130 million.

More than 100 Komen-supported research labs are actively studying metastatic breast cancer to understand why it occurs and how to treat or prevent it.

“We know a lot about breast cancer, but a lot is to be learned. Susan G. Komen is providing us with funding to pursue research that is saving lives.”

—Dr. Kristi Egland,
Career Catalyst Research grantee